In the first three quarters of 2019, the R & D expenditure of these three pharmaceutical companies ranked first

[trends of pharmaceutical network industry] in recent years, with the continuous promotion of medical reform policies such as volume procurement in China, the market growth of the pharmaceutical industry has entered a steady growth stage, while the internal differentiation of the industry continues to intensify, and innovation has become the development direction of the industry It is generally agreed in the industry that innovation in medicine cannot be achieved without investment in R & D in addition to the long R & D cycle, only companies with deep accumulation and strong anti risk ability have such a foundation Therefore, in the long run, the industry leading enterprises with large R & D investment and perfect variety layout will be the big winners of market integration So, in the current pharmaceutical enterprises in China, what are the enterprises with strong R & D investment ability? Data shows that in the first three quarters of 2019, the total revenue of 314 listed pharmaceutical companies exceeded 1.33 trillion yuan, realizing a net profit of 113.274 billion yuan, and the total R & D expenditure in the same period was 29.551 billion yuan, accounting for 2.22% of the total revenue Among them, the private listed companies with a revenue scale of over 10 billion ranked first in R & D expenditure scale, namely Hengrui pharmaceutical, Fosun Pharmaceutical and Mindray medical, with R & D expenditure of 2.899 billion yuan, 1.290 billion yuan and 1.084 billion yuan respectively, accounting for more than 10% of the revenue According to the financial data of Hengrui pharmaceutical, in the first three quarters of 2019, the R & D expenditure of Hengrui pharmaceutical totaled 2.899 billion yuan, accounting for 17.11% of the revenue The company said in the announcement that the significant increase in R & D expenses was due to the increase in R & D project investment during the reporting period The author noted that relevant financial reports show that since 2011, the R & D investment intensity of Hengrui pharmaceutical has been maintained at more than 10%, including 2.67 billion yuan in 2018 Through continuous R & D investment, Hengrui pharmaceutical has ushered in the harvest stage At present, the product line of Hengrui medicine mainly covers anti-tumor, surgical anesthesia, contrast agent and other fields, while the follow-up R & D pipeline further expands to the fields of immune diseases, diabetes and other major diseases At present, five innovative drugs of Hengrui medicine have been approved for marketing, namely, iricoxib, apatinib, tiopefiglitazidine, pyrrolidine and carrizumab, and more than 30 innovative drugs are under clinical research Fosun Pharma's R & D investment in 2018 was 1.480 billion yuan, up to the third quarter of 2019, it was 1.290 billion yuan, about half of Hengrui Pharma's According to the data, Fosun Pharmaceutical is an enterprise integrating pharmaceutical research and development, pharmaceutical circulation, medical services, medical diagnosis and medical devices In recent years, Fosun Pharmaceutical has continuously enriched its product lines through acquisition, and formed three business segments, namely, pharmaceutical manufacturing and R & D, medical services, medical devices and medical diagnosis According to the industry, at present, multiple circuits of Fosun Pharmaceutical have gradually entered the harvest period, and the competitiveness of the company is still strengthening There are many focuses in the later stage, which are mainly reflected in Kate, hongchuang, Fuhong Hanlin and gladpharma These layouts will continue to strengthen the domestic and international competitiveness of Fosun Pharmaceutical in the future, and finally transform into the company's revenue and profit In the first three quarters of 2019, R & D expenditure of Mindray medical reached 1.084 billion yuan, up 11.9% year on year In addition, according to the company's financial statements over the years, from 2015 to 2017, the annual R & D expenditure of Mindray medical is about 1 billion yuan, and in 2018, it has reached 1.42 billion yuan In the context of increasing R & D investment, in recent years, the performance of Mindray medical has continued to grow at a high level, with double-digit growth in revenue for three consecutive years, and net profit growth of more than 40% In the first three quarters of 2019, Meirui medical realized a revenue of 12.379 billion yuan, a year-on-year increase of 20.42%; and a net profit of 3.671 billion yuan, a year-on-year increase of 26.74% In addition, in terms of technology research and development achievements, Mindray medical has gained a lot In the first half of 2019 alone, the company launched several new and upgraded heavy-duty products and versions, such as dc-80 x-insight, bs-2000m full-automatic biochemical analyzer, cl-6000i M2 full-automatic chemiluminescent immunoanalyzer, which attracted wide attention of the market.